Nippon India PHARMA Fund - G

NAV ₹496.748 ↑ 3.00 (0.61 %) as on 15 May 25

Table of Contents

Scheme Objective
NAV Price Chart
Returns
- Historical Returns
- Compounded Returns
Growth Of 10k Over Years
Holdings / Portfolio
All Plan & Options
Fund Manager Information
Custodians
Registrar & Transfer Agent (RTA)
Administrator Companies
Auditors

Scheme Objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a CAGR return of 20.5% since its launch. Ranked 35 in Sectoral category. Return for 2024 was 34% , 2023 was 39.2% and 2022 was -9.9% .

Below is the key information for Nippon India Pharma Fund

NAV as on 15 May 25	₹496.748 ↑ 3.00 (0.61 %)
Net Assets (AUM) as on 31 Mar 2025	₹8,081 Cr.
Launch Date	5 Jun 2004
Category	Equity - Sectoral
Rating	☆☆
Type	Open Ended Fund
Risk	High
AMC	Nippon Life Asset Management Ltd.

Alpha Ratio	-4.46
Expense Ratio	1.88 %
Sharpe Ratio	0.353
Information Ratio	-0.49
Benchmark	Not Available
Min Investment	₹5,000
Min SIP Investment	₹100
Exit Load	0-1 Years (1%),1 Years and above(NIL)

NAV Price Chart

Returns

Annual Compounded Returns

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 15 May 25

Duration	Returns
1 Month	4.8%
3 Month	6.3%
6 Month	-0.8%
1 Year	15.2%
3 Year	22.6%
5 Year	22.4%
10 Year
15 Year
Since launch	20.5%

Historical Annual Returns

Historical performance (Yearly) on absolute basis

Year	Returns
2024	34%
2023	39.2%
2022	-9.9%
2021	23.9%
2020	66.4%
2019	1.7%
2018	3.6%
2017	7.6%
2016	-10.6%

Growth of 10k Over Years

Date	Value
30 Apr 20	₹10,000
30 Apr 21	₹15,389
30 Apr 22	₹15,981
30 Apr 23	₹15,783
30 Apr 24	₹23,851
30 Apr 25	₹27,660

Asset Allocation

Asset Class	Value
Cash	0.29%
Equity	99.71%

Sector Allocation

Sector	Value
Health Care	99.71%

Top Securities Holdings / Portfolio

Holdings/Securities

Name	Global Industry	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Oct 09 \| SUNPHARMA	Drug Manufacturers - Specialty & Generic	14%	₹1,146 Cr	6,256,349
Divi's Laboratories Ltd (Healthcare) Equity, Since 31 Mar 12 \| DIVISLAB	Drug Manufacturers - Specialty & Generic	10%	₹791 Cr	1,298,808
Lupin Ltd (Healthcare) Equity, Since 31 Aug 08 \| 500257	Drug Manufacturers - Specialty & Generic	6%	₹521 Cr	2,483,991 ↓ -414,135
Cipla Ltd (Healthcare) Equity, Since 31 May 08 \| 500087	Drug Manufacturers - Specialty & Generic	6%	₹496 Cr	3,200,000
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 30 Sep 20 \| APOLLOHOSP	Medical Care Facilities	5%	₹453 Cr	648,795
Dr Reddy's Laboratories Ltd (Healthcare) Equity, Since 30 Jun 11 \| DRREDDY	Drug Manufacturers - Specialty & Generic	5%	₹434 Cr	3,662,170
GlaxoSmithKline Pharmaceuticals Ltd (Healthcare) Equity, Since 31 Aug 22 \| GLAXO	Drug Manufacturers - General	4%	₹300 Cr	1,011,921
Medplus Health Services Ltd (Healthcare) Equity, Since 30 Nov 22 \| 543427	Pharmaceutical Retailers	4%	₹292 Cr	3,627,277
Vijaya Diagnostic Centre Ltd (Healthcare) Equity, Since 30 Sep 21 \| 543350	Diagnostics & Research	3%	₹283 Cr	2,831,564
Abbott India Ltd (Healthcare) Equity, Since 31 May 11 \| ABBOTINDIA	Drug Manufacturers - Specialty & Generic	3%	₹267 Cr	88,883 ↓ -2,050

1 - 10 of 41

Ready to Invest?
Talk to our investment specialist

Fund Managers

Name	Since	Tenure
Sailesh Raj Bhan	1 Apr 05	20.09 Yr.
Kinjal Desai	25 May 18	6.94 Yr.

Custodians

Company	Address
Deutsche Bank AG	Deutsche Bank AG,Kodak House, 22, D.N. Road,

Registrar & Transfer Agent

KFin Technologies Ltd
Address	138 -Suyesh Solitaire, Nr. Podar International School,Kudasan, Gandhinagar, Gujarat
FAX	N.A
Email	N.A

Administrator Companies

Company	Address
Nippon India Mutual Fund	9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051

Auditors

Company	Address
Haribhakti & Co. Chartered Accountants	42, Free Press House,4th Floor,,215, Nariman Point,

All Plan & Options

Fund and Plan	NAV	6 Month	1 Year	3 Year	5 Year
Nippon India Pharma Fund Normal Dividend, Payout	₹115.78 ↑ 0.70	-1.64 %	14.23 %	21.97 %	24.99 %
Nippon India Pharma Fund Normal Dividend, Reinvestment	₹115.78 ↑ 0.70	-1.64 %	14.23 %	21.97 %	24.99 %
Nippon India Pharma Fund Growth	₹496.748 ↑ 3.00	-0.83 %	15.18 %	22.61 %	22.45 %
Data as on 15 May 25

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.

Shepard Technologies Pvt. Ltd : 1808, Solus, Hiranandani Estate, Thane, Maharashtra - 400607

AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153

Mutual fund investments are subject to market risks. Please read the scheme information and other related documents carefully before investing. Past performance is not indicative of future returns. Please consider your specific investment requirements before choosing a fund, or designing a portfolio that suits your needs.

Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.